Abstract 648P
Background
As extended analysis of the COVID-DELAY study, we aimed to assess COVID-19 impact on diagnosis, staging and treatment outcomes of CRC patients in 2021 and 2022 compared to 2019 and 2020.
Methods
All consecutive newly diagnosed CRC patients referred to 8 Italian Oncology Departments between March and December 2019, 2020, 2021, and 2022 were evaluated. Access rate (number of patients/year), demographic characteristics, diagnostic and therapeutic temporal intervals (between date of symptoms onset, radiological and cytohistological diagnosis, treatment start, and first radiological evaluation), as well as PFS and OS were assessed and compared.
Results
Compared to 2019 (n=485), a reduction in new CRC cases was found in 2020 (n=390, -19.6%). On the other hand, a progressive increase in new CRC diagnosis was found in 2021 (n= 461, +18.2%) and 2022 (n= 509, +30.5%), compared to 2020. A higher rate of stage IV tumours was diagnosed in 2020 (31.3%) and 2021 (29.6%) compared to 2019 (20.8%), with a normalization in 2022 (22.8%) (p<0.001); a lower number of patients has been discussed in multidisciplinary tumor boards in 2020 (22.1%) compared to 2019 (34.9%), 2021 (37.0%), and 2022 (47.6%) (p<0.001). A significant difference in terms of temporal interval between histological diagnosis and first oncological examination (median of 31 vs. 38 days, respectively, p=0.004), cytohistological diagnosis and systemic treatment start (median of 52 vs. 58 day, p<0.001), first oncological appointment and systemic treatment start (median of 52 compared to 58 days, p=0.034), was found between 2020 and 2021-2022 years, respectively. At multivariate analysis, the 2021-2022 years confirmed to be associated with a reduction in the risk of disease progression compared to 2020 (HR=0.71 (0.53-0-97); p=0.031).
Conclusions
A worsening drop in CRC diagnosis in 2020, with a progressive increase in 2021 and 2022, in parallel with a higher incidence of late-stage CRC diagnosed in 2020 and 2021. This might have affected some diagnostic-therapeutic time intervals in 2021-2022 years compared to 2020.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11